[144] HEALTHEQUITY, INC. SEC Filing

Rhea-AI Filing Summary

HEALTHEQUITY, Inc. filing a Form 144 notifies a proposed sale of 1,058 shares of common stock on 10/06/2025 through Morgan Stanley Smith Barney on NASDAQ. The filing lists an aggregate market value of $93,704.27 and reports 86,156,334 shares outstanding.

The shares originated from restricted stock vesting on three dates: 03/30/2022 (318 shares), 03/29/2023 (427 shares), and 03/27/2024 (313 shares). Payment is listed as compensation. The filer states there were no sales in the past 3 months and affirms no undisclosed material adverse information.

Positive

• Clear compliance with Rule 144 by providing broker, share counts, and vesting dates
• No sales in past 3 months reported, simplifying aggregation rules for this notice

Negative

• None.

Insights

Equity Securities Analyst

Officer/insider selling a small block of vested restricted shares via a broker on 10/06/2025.

The notice records a proposed sale of 1,058 common shares for an aggregate market value of $93,704.27, executed through Morgan Stanley Smith Barney on NASDAQ. The underlying shares were received from restricted stock vesting across 2022–2024 and are classified as compensation.

Key dependencies are the execution of the broker sale on 10/06/2025 and the absence of other reported sales in the prior three months. Investors may note the filer’s certification that no undisclosed material adverse information exists as of the filing.

Corporate Governance Specialist

Transaction appears procedural: vesting-to-sale of compensation shares with standard Rule 144 notice.

The filing documents the transfer path from issuer-granted restricted stock to proposed market sale, which follows typical compliance steps for insiders selling restricted shares under Rule 144. The broker, share counts by vesting date, and payment nature (compensation) are explicitly listed.

Materiality is limited: total shares proposed represent a small fraction of the 86,156,334 outstanding shares. Watch for the actual trade execution on 10/06/2025 and any subsequent filings that report completed sales.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Morgan Stanley Smith Barney 2000 Westchester Ave Purchase NY 10577-2530	1058	93704.27	86156334	10/06/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/30/2022	Restricted Stock Vesting	ISSUER			318	10/06/2025	Compensation
Common Stock	03/29/2023	Restricted Stock Vesting	ISSUER			427	10/06/2025	Compensation
Common Stock	03/27/2024	Restricted Stock Vesting	ISSUER			313	10/06/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does HEALTHEQUITY (HQY) Form 144 report?

It reports a proposed sale of 1,058 common shares through Morgan Stanley Smith Barney on 10/06/2025 with aggregate market value $93,704.27.

Were the shares acquired as compensation or purchase?

The filing lists the shares as acquired via restricted stock vesting and the payment nature is recorded as compensation.

How many shares were granted on each vesting date?

The filing shows 318 shares vested on 03/30/2022, 427 on 03/29/2023, and 313 on 03/27/2024.

Does this filing indicate prior sales by the filer in the last 3 months?

No. The form states "Nothing to Report" for securities sold during the past 3 months.

How large is the proposed sale relative to shares outstanding?

The proposed 1,058 shares are against 86,156,334 shares outstanding as stated in the filing.